The Impact of Co-Morbid OCD--ADHD {#s1}
=================================

The prevalence and functional impairment for OCD--ADHD appears substantial. A recent study has shown a prevalence rate of 11.8% for co-morbid ADHD in OCD-affected individuals ([@B1]). Pediatric OCD patients showed a prevalence estimate of 25.5% for co-morbid ADHD ([@B2]). Co-morbid OCD--ADHD from a young age was associated with greater OCD severity and persistence of symptoms in a prospective follow-up period ([@B3]), and poorer prognosis ([@B4]). Studies suggest that patients experience more disabling OCD symptoms when ADHD is also present, but the actual nature of OCD symptoms are not significantly different from patients with OCD alone ([@B5], [@B6]). The varying prevalence of co-morbidity is most likely due to differences in study definitions and methodology, but raises questions on whether both these disorders are actually present simultaneously, or whether one disorder may mimic or predispose an individual to the other disorder ([@B7]). Their co-morbidity also behoves clinicians to consider undiagnosed ADHD in treatment-resistant OCD, and vice versa.

Previously, ADHD and OCD were viewed very distinctly on an impulsive--compulsive continuum. However, there has been increasing awareness of the cross-cutting nature of the symptoms domains of impulsivity and compulsivity ([@B8]). Impulsivity is characterized by inability to resist impulses and urges, delaying gratification deficits, unreflective decision making, and premature behaviour. Compulsivity is characterized by perseverative and repetitive action, and is ruminative and rigid in nature. Both these constructs co-occur in separate cases of ADHD and OCD at varying severities. Patients with OCD can feel urges to enact compulsions when prevented from doing so, and may suddenly yield to them, despite full awareness of the negative consequences. Patients with ADHD may chance upon an immediately pleasurable activity that they then repeat for ongoing pleasurable effect.

There is overlap between the two conditions with features such as impulsivity observed in both groups but at markedly higher levels in those with ADHD ([@B9]).

Neurobiology of ADHD and OCD {#s2}
============================

Frontostriatal pathophysiology appears to be involved in both disorders (see [**Figures 1A, B**](#f1){ref-type="fig"}). Brain-mapping studies have shown that patients with ADHD and OCD have shared but also disorder-specific brain dysfunctions during interference inhibition and attention allocation suggesting to be the result of alternate dopamine modulation of striatal brain regions ([@B10]). Predominantly, the overlap in activation deficits in ADHD and OCD are in frontostriato-insular-cerebellar regions. These regions play a role in self-control and temporal foresight, and govern impulsivity with choices ([@B11]).

![**(A)** The Neurobiology of OCD ([@B12]); overactivation of the cortico-striatal-thalamic-cortical loop is associated with obsessions. **(B)** Brain changes in ADHD ([@B13]); reduced activation of prefrontal and striatal regions including the nucleus accumbens and basal ganglia structures.](fpsyt-10-00557-g001){#f1}

While ADHD is characterized with frontostriatal hypoactivity ([@B14]), OCD commonly appears hyperactive in this region on functional imaging. Patients with OCD alone showed abnormalities in functioning of the right orbitofrontal and rostrolateral prefrontal cortex ([@B15]). Conversely, the disinhibition and impulsivity of ADHD are associated with hypoperfusion of prefrontal regions ([@B10]).

There are also disorder-specific structural abnormalities. Patients with OCD tend to have larger and hyperfunctioning insular-striatal regions, whereas those with ADHD have smaller and underfunctioning ventrolateral prefrontal/insular-striatal regions ([@B16]).

The degree of frontostriatal hyperactivity or hypoactivity also appears to underpin symptoms in both OCD and ADHD. In ADHD, there is an inverse correlation between impulsive symptoms with activity in prefrontal ([@B17], [@B18]) and striatal ([@B19]) regions. Recent findings support this by highlighting an inverse correlation between frontostriatal functional connectivity and symptom severity in ADHD ([@B14], [@B20]). Alternately, OCD demonstrates a positive association between symptom severity and brain activity ([@B21]--[@B24]). A recent study comparing OCD and ADHD patients identified that the correlation of symptom severity with frontostriatal brain activity was positive in the OCD sample but negative in the ADHD sample ([@B9]). These contrasting findings may support the hypothesis that these disorders lie on opposite ends of a clinical impulsive--compulsive continuum.

However, despite these differences, OCD and ADHD appear to share similar neuropsychological impairments in executive functions, particularly inhibition deficit ([@B25]). This suggests that different neurobiological processes can lead to similar dysfunction ([@B25]). When using learned reward expectancies to guide decision making, findings suggest an overlap in deficits, as well as shared dysfunction in medio-fronto-striato-limbic brain regions. However, results also suggest the existence of unique dysfunction in the ventromedial orbitofrontal cortex in OCD, and in the right putamen in ADHD, indicating additional disorder-specific abnormalities ([@B26]).

Treatment Implications for Co-Morbid OCD--ADHD {#s3}
==============================================

Based on current neurobiological knowledge, OCD and ADHD appear to have different and apparently opposing deficits in the frontostriatal and related areas. This may have treatment implications in co-morbid OCD--ADHD.

The effectiveness of selective serotonin reuptake inhibitors (SSRIs) in the treatment of OCD has been well established ([@B27]). These agents regulate hyperactivity in the frontostriatal region of the brain ([@B28], [@B29]). In cases of OCD patients who exhibit only partial response to SSRIs, antipsychotics with dopamine blocking properties appear to have a useful effect in augmenting serotonin reuptake inhibition ([@B30]).

On the other hand, first line treatment for ADHD has been methylphenidate or dexamphetamine for several decades. Stimulant medication increases prefrontal activation and significantly improves both clinical symptomology and neurocognitive processes through modulation of dopamine reuptake. In addition, ADHD-tailored CBT which address academic and organizational skills training, problem-solving and prioritizing tasks, as well as managing unhelpful thinking and behavioral patterns, demonstrate encouraging improvements in adolescents and adults ([@B31], [@B32]).

Some literature suggests that stimulants can exacerbate and provoke OCD symptoms. While this may be consistent with the theoretical understanding of dopaminergic prefrontal hyperactivity, this evidence is mostly anecdotal and remains limited ([@B33]--[@B37]).

In terms of co-morbid OCD--ADHD, there is evidence to support that treating OCD with SSRIs and cognitive behaviour therapy with exposure response prevention (CBT+ERP) improves attentional symptoms ([@B38]). This may be mediated through SSRI activation of BDNF and other neurotrophic factors that lead to neuronal growth in networks responsible for working memory and processing speed ([@B39]--[@B41]).

There is also evidence that treating ADHD with stimulants improves co-morbid obsessive--compulsive symptoms. CBT+ERP has demonstrated efficacy for children and adults with OCD, but untreated co-morbid ADHD diminishes treatment response on the OCD ([@B7]). Stimulant treatment improves attention, conscious learning and retention of CBT skills and allows patients to apply skills when obsessive thoughts recur.

Limiting treatment to only one disorder when both are present appears to be associated with poorer outcomes. A study investigating the use of paroxetine in patients with co-morbid ADHD found that the OCD response rates were significantly less than in patients with OCD alone. The presence of ADHD co-morbidity was also associated with a greater rate of OCD relapse ([@B42]). Conversely, case studies suggest that treating both disorders concurrently can be beneficial for both disorders ([@B43]).

It would therefore seem prudent to treat both conditions concurrently when they are both present and severe enough to warrant biological and psychological treatments. Additionally, screening for disorders of addiction is important due to the heightened cumulative risk in these individuals. Despite the lack of randomized controlled trials in clinical populations, it would be reasonable to start with standard treatments for both, such as SSRIs for OCD and psychostimulants such as methylphenidate and dexamphetamine for ADHD. Pharmacological treatments should be introduced one at a time to avoid confusion around treatment response and side-effects. This is especially relevant given the possibility of worsening OCD with stimulants. Monitoring progress through routine use of established instruments such as the Yale Brown Obsessive Compulsive Scale for OCD ([@B44]) and ADHD Rating Scale 5 or similar ([@B45]) is appropriate.

Transcranial magnetic stimulation (TMS) has a limited but growing body of evidence for its efficacy in both ADHD ([@B46]--[@B48]) and OCD ([@B49], [@B50]) Combined with its relative safety, TMS may be a viable option for treating co-morbid ADHD and OCD, pending further clinical trials. Additionally, where symptoms remain resistant to both pharmacological and psychological approaches and OCD symptoms significantly disrupt daily functioning, intensive residential treatment may be considered if available ([@B51]).

Conclusion {#s4}
==========

The treatment of OCD--ADHD co-morbidity in children, and to an even greater extent in adults, remains challenging. ADHD and OCD are not mutually exclusive and do co-exist ([@B52]). They share dysfunction in impulsivity, inattention, and executive function while appearing to have opposing pathophysiology and phenomenology. Treating one without the other leads to poorer outcomes in both, while treating both simultaneously is associated with better outcomes. Further research is needed to better understand the neurobiological interplay between both disorders, refine our nosology of them, and guide treatment options.
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